Beginning this month, the Galleri test will be offered to eligible patients through the OHSU Knight Cancer Institute
OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance the delivery of cancer care. (Credit: Michal Jarmoluk from Pixabay)
GRAIL, LLC, a healthcare company whose mission is to detect cancer early, today announced a collaboration with the Knight Cancer Institute at Oregon Health & Science University (OHSU) to offer Galleri®, GRAIL’s multi-cancer early detection (MCED) blood test. OHSU will provide patients access to Galleri via a pilot program to help find signals of cancer in earlier stages and advance the delivery of cancer care.
Beginning this month, the Galleri test will be offered to eligible patients through the OHSU Knight Cancer Institute. The OHSU Knight Cancer Institute is at the forefront of multi-cancer early detection, including serving as a founding member of the MCED consortium, a group of leading cancer-focused organizations evaluating technologies that have the potential to reduce cancer mortality through earlier detection and providing guidance for their clinical use.
“At GRAIL, we are focused on detecting cancer early, when treatments are more effective and there is potential for cure,” said Dr. Josh Ofman, president and chief medical officer at GRAIL. “We are honored to work alongside the preeminent team of researchers and clinicians at the OHSU Knight Cancer Institute who share our vision and are committed to bringing their patients the benefits of earlier cancer detection.”
More than 600,000 people die from cancer each year in the U.S., according to the American Cancer Society. This is in large part because the majority of cancers are found too late when outcomes are often poor. Recommended screening tests save lives, but only cover five cancer types in the U.S.: breast, colon, cervical, prostate, and, in high-risk smokers, lung. In fact, 71% of cancer deaths have no recommended early detection screening at all.
“Multi-cancer early detection is a true game-changing technology in how we detect and treat cancer,” said Tom Beer, M.D., deputy director of the OHSU Knight Cancer Institute and chief medical officer of the Knight Cancer Institute’s Cancer Early Detection Advanced Research (CEDAR) Program. “After evaluating how the Galleri test worked in the clinical trial setting, we are now able to offer eligible patients access to the test.”
In a clinical study, Galleri demonstrated the ability to detect more than 50 types of cancer, as defined by the American Joint Committee on Cancer Staging Manual, over 45 of which lack recommended screening tests today, with a low false positive rate of less than 1%. When cancer is detected, Galleri can determine the cancer signal origin with high accuracy.
OHSU is also a leading partner in the interventional PATHFINDER 2 study evaluating the implementation and performance of Galleri in a clinical care setting. Initial results from the first PATHFINDER study were presented by Dr. Beer at the 2021 ASCO Annual Meeting and demonstrated Galleri’s performance was consistent with findings from previous observational studies, underscoring the potential real-world ability of Galleri to find deadly cancers earlier.
Source: Company Press Release